Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients

Background: Carriership with methicillin resistant <i>Staphylococcus aureus</i> (MRSA) is a risk for the development of secondary infections in critically ill patients. Previous studies suggest that enteral vancomycin is able to eliminate enteral carriership with MRSA. Data on individual...

Full description

Bibliographic Details
Main Authors: Sophie H. Buitinck, Matty Koopmans, Rogier M. Determann, Rogier R. Jansen, Peter H. J. van der Voort
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/11/2/263
_version_ 1797483369357901824
author Sophie H. Buitinck
Matty Koopmans
Rogier M. Determann
Rogier R. Jansen
Peter H. J. van der Voort
author_facet Sophie H. Buitinck
Matty Koopmans
Rogier M. Determann
Rogier R. Jansen
Peter H. J. van der Voort
author_sort Sophie H. Buitinck
collection DOAJ
description Background: Carriership with methicillin resistant <i>Staphylococcus aureus</i> (MRSA) is a risk for the development of secondary infections in critically ill patients. Previous studies suggest that enteral vancomycin is able to eliminate enteral carriership with MRSA. Data on individual effects of this treatment are lacking. Methods: Retrospective analysis of a database containing 15 year data of consecutive patients from a mixed medical-(cardio)surgical 18 bedded intensive care unit was conducted. All consecutive critically ill patients with enteral MRSA carriership detected in throat and/or rectal samples were collected. We analyzed those with follow-up cultures to determine the success rate of enteral vancomycin. Topical application of 2% vancomycin in a sticky oral paste was performed combined with a vancomycin solution of 500 mg four times daily in the nasogastric tube. This treatment was added to a regimen of selective digestive tract decontamination (SDD) to prevent ICU acquired infection. Results: Thirteen patients were included. The mean age was 65 years and the median APACHE II score was 21. MRSA was present in the throat in 8 patients and in both throat and rectum in 5 patients. In all patients MRSA was successfully eliminated from both throat and rectum, which took 2–11 days with a median duration until decontamination of 4 days. Secondary infections with MRSA did not occur. Conclusions: Topical treatment with vancomycin in a 2% sticky oral paste four times daily in the nasogastric tube was effective in all patients in the elimination of MRSA and prevented secondary MRSA infections.
first_indexed 2024-03-09T22:46:57Z
format Article
id doaj.art-ec8527e5d5714cce805c52ee66c2e397
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-09T22:46:57Z
publishDate 2022-02-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-ec8527e5d5714cce805c52ee66c2e3972023-11-23T18:29:14ZengMDPI AGAntibiotics2079-63822022-02-0111226310.3390/antibiotics11020263Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill PatientsSophie H. Buitinck0Matty Koopmans1Rogier M. Determann2Rogier R. Jansen3Peter H. J. van der Voort4Department of Intensive Care, OLVG Hospital, P.O. Box 95500, 1090 HM Amsterdam, The NetherlandsDepartment of Intensive Care, OLVG Hospital, P.O. Box 95500, 1090 HM Amsterdam, The NetherlandsDepartment of Intensive Care, OLVG Hospital, P.O. Box 95500, 1090 HM Amsterdam, The NetherlandsDepartment of Medical Microbiology, OLVG Hospital, Oosterpark 9, 1091 AC Amsterdam, The NetherlandsDepartment of Critical Care Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB Groningen, The NetherlandsBackground: Carriership with methicillin resistant <i>Staphylococcus aureus</i> (MRSA) is a risk for the development of secondary infections in critically ill patients. Previous studies suggest that enteral vancomycin is able to eliminate enteral carriership with MRSA. Data on individual effects of this treatment are lacking. Methods: Retrospective analysis of a database containing 15 year data of consecutive patients from a mixed medical-(cardio)surgical 18 bedded intensive care unit was conducted. All consecutive critically ill patients with enteral MRSA carriership detected in throat and/or rectal samples were collected. We analyzed those with follow-up cultures to determine the success rate of enteral vancomycin. Topical application of 2% vancomycin in a sticky oral paste was performed combined with a vancomycin solution of 500 mg four times daily in the nasogastric tube. This treatment was added to a regimen of selective digestive tract decontamination (SDD) to prevent ICU acquired infection. Results: Thirteen patients were included. The mean age was 65 years and the median APACHE II score was 21. MRSA was present in the throat in 8 patients and in both throat and rectum in 5 patients. In all patients MRSA was successfully eliminated from both throat and rectum, which took 2–11 days with a median duration until decontamination of 4 days. Secondary infections with MRSA did not occur. Conclusions: Topical treatment with vancomycin in a 2% sticky oral paste four times daily in the nasogastric tube was effective in all patients in the elimination of MRSA and prevented secondary MRSA infections.https://www.mdpi.com/2079-6382/11/2/263vancomycinoralMRSAcarriershipcolonizationSDD
spellingShingle Sophie H. Buitinck
Matty Koopmans
Rogier M. Determann
Rogier R. Jansen
Peter H. J. van der Voort
Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
Antibiotics
vancomycin
oral
MRSA
carriership
colonization
SDD
title Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
title_full Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
title_fullStr Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
title_full_unstemmed Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
title_short Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
title_sort enteral vancomycin to eliminate mrsa carriership of the digestive tract in critically ill patients
topic vancomycin
oral
MRSA
carriership
colonization
SDD
url https://www.mdpi.com/2079-6382/11/2/263
work_keys_str_mv AT sophiehbuitinck enteralvancomycintoeliminatemrsacarriershipofthedigestivetractincriticallyillpatients
AT mattykoopmans enteralvancomycintoeliminatemrsacarriershipofthedigestivetractincriticallyillpatients
AT rogiermdetermann enteralvancomycintoeliminatemrsacarriershipofthedigestivetractincriticallyillpatients
AT rogierrjansen enteralvancomycintoeliminatemrsacarriershipofthedigestivetractincriticallyillpatients
AT peterhjvandervoort enteralvancomycintoeliminatemrsacarriershipofthedigestivetractincriticallyillpatients